SCHEMBL9976007

SCHEMBL9976007

O=c1cc(/C=C/c2ccc(Cl)cc2)oc2ccccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.78
MAPT P10636 4/20 0.78
HPGD P15428 4/20 0.78
ALDH1A1 P00352 3/20 0.78
SMN1; SMN2 Q16637 3/20 0.78
NPC1 O15118 2/20 0.78
RAB9A P51151 2/20 0.78
NPSR1 Q6W5P4 1/20 0.78
MAOA P21397 2/20 0.64
MAOB P27338 2/20 0.64
TNKS O95271 2/20 0.56
HTT P42858 1/20 0.51
STS P08842 1/20 0.49
GRM4 Q14833 1/20 0.49
NQO1 P15559 1/20 0.48
GABRP O00591 2/20 0.47
GABRD O14764 2/20 0.47
GABRA1 P14867 2/20 0.47
GABRB1 P18505 2/20 0.47
GABRG2 P18507 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435366 0.88 HPGD (1.00) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL2465240 0.88 HPGD (1.00) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL9976005 0.85 KDM4E (0.78) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL9976006 0.83 HPGD (0.69) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL9975965 0.82 KDM4E (0.78) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL10615084 0.82 KDM4E (0.78) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL9976004 0.82 KDM4E (0.72) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL9976009 0.82 KDM4E (0.72) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL9975962 0.82 MAPT (0.80) KDM4EMAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL9976010 0.81 MAPT (0.70) KDM4EMAPTHPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
WO-2012087889-A2 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-28 WO disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157465-A1 DNA METHYLATION INHIBITORS MECP2, DNMT1, DNMT3B KDM4E 427/4885MAPT 3677/4885HPGD 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.